ProteoNic and Oxford Expression Technologies sign UNic™ license for use in flashBAC™

Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

ProteoNic announces closing of financing round

Leiden, The Netherlands, September 28, 2011 – Dutch biotech company ProteoNic B.V. announces successful completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund (FIF), with existing shareholders participating. The funding will be used to accelerate commercialization of ProteoNic’s proprietary UNic™ recombinant protein yield enhancement technology and expand the company’s capabilities in the area of cell line generation and contract services.

ProteoNic and Oxford ET join forces combining UNic™ with flashBAC™ protein expression platform

March 8, 2011 – Leiden, Netherlands/Oxford, United Kingdom – ProteoNic BV, the protein production experts, and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have joined forces in the field of recombinant protein production technology with the aim of jointly offering a superior platform and services. Several projects combining ProteoNic’s UNic™ translation enhancement elements with OET’s flashBAC™ system have been initiated.